ETF Holdings Breakdown of CYTK

CYTK institutional holdings

The adjusted close for CYTK on 2025-11-12 was 65.94

The following institutional investment holdings of CYTK have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-12	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	78,664	USD 5,187,104 -0.8%	65.94
2025-11-12	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	75,162 -0.3%	USD 4,956,182 -1.2%	65.94
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	77,566	USD 5,114,702	65.94
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	77,566 0.3%	USD 5,114,702 -0.6%	65.94
2025-11-12	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	7,268	USD 479,252 -0.8%	65.94
Total =		316,226	USD 20,851,942

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with CYTK

Cytokinetics Upsizes Convertible Notes Offering To $650 Mln

(RTTNews) - Cytokinetics Inc. (CYTK) announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a private placement. The aggregate principal amount of the offering was increased from the previously announced of - 2025-09-17 02:15:35

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives $75.38 Average Target Price from Brokerages

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has received an average rating of “Moderate Buy” from the fifteen research firms that are covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has issued a strong buy recommendation on the company. The […] - 2025-09-12 02:48:52

Barclays Raises Cytokinetics (NASDAQ:CYTK) Price Target to $71.00

Cytokinetics (NASDAQ:CYTK – Get Free Report) had its price objective upped by investment analysts at Barclays from $53.00 to $71.00 in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s target price indicates a potential upside of 42.71% from the […] - 2025-09-05 05:11:01

Cytokinetics (NASDAQ:CYTK) Earns Buy Rating from Needham & Company LLC

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Needham & Company LLC in a note issued to investors on Tuesday,Benzinga reports. They presently have a $72.00 price objective on the biopharmaceutical company’s stock. Needham & Company LLC’s target price suggests a potential upside of 44.03% from the […] - 2025-09-04 04:34:50

Vanguard Group Inc. Sells 66,274 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Vanguard Group Inc. decreased its position in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 0.6% in the 1st quarter, HoldingsChannel reports. The fund owned 11,849,547 shares of the biopharmaceutical company’s stock after selling 66,274 shares during the period. Vanguard Group Inc. owned approximately 0.10% of Cytokinetics worth $476,233,000 as of its most recent filing with […] - 2025-08-15 05:04:48

Wall Street Zen Upgrades Cytokinetics (NASDAQ:CYTK) to “Hold”

Cytokinetics (NASDAQ:CYTK – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research note issued to investors on Sunday. CYTK has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a […] - 2025-08-12 02:18:50

XTX Topco Ltd Cuts Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)

XTX Topco Ltd trimmed its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 23.8% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 7,357 shares of the biopharmaceutical company’s stock after selling 2,293 shares during the period. XTX Topco Ltd’s holdings in Cytokinetics were worth $296,000 at the end of the […] - 2025-08-11 05:44:57

Citigroup Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $77.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price target reduced by Citigroup from $80.00 to $77.00 in a research note published on Friday morning,Benzinga reports. Citigroup currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also recently issued reports on CYTK. Bank of America reduced their target […] - 2025-08-11 05:06:52

KLP Kapitalforvaltning AS Acquires 600 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

KLP Kapitalforvaltning AS raised its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 2.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 23,600 shares of the biopharmaceutical company’s stock after acquiring an additional 600 shares during the quarter. KLP Kapitalforvaltning AS’s […] - 2025-07-29 06:16:49

Edgestream Partners L.P. Makes New $732,000 Investment in Cytokinetics, Incorporated (NASDAQ:CYTK)

Edgestream Partners L.P. acquired a new stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 18,216 shares of the biopharmaceutical company’s stock, valued at approximately $732,000. Other hedge funds and other institutional investors have […] - 2025-07-20 05:25:05

Principal Financial Group Inc. Purchases 358,778 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Principal Financial Group Inc. grew its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 132.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 629,911 shares of the biopharmaceutical company’s stock after buying an additional 358,778 […] - 2025-07-09 05:45:06

Noteworthy Thursday Option Activity: CYTK, GOOG, HOFT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cytokinetics Inc (Symbol: CYTK), where a total of 7,451 contracts have traded so far, representing approximately 745,100 underlying shares. That amounts to about 46.8% o - 2025-06-12 18:17:36

Cytokinetics (NASDAQ:CYTK) Given New $53.00 Price Target at JPMorgan Chase & Co.

Cytokinetics (NASDAQ:CYTK – Get Free Report) had its price target cut by JPMorgan Chase & Co. from $71.00 to $53.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of […] - 2025-06-11 02:44:48

Cetera Investment Advisers Decreases Position in Cytokinetics, Incorporated (NASDAQ:CYTK)

Cetera Investment Advisers decreased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 82.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 4,551 shares of the biopharmaceutical company’s stock after selling 21,484 shares during the quarter. Cetera Investment Advisers’ holdings in Cytokinetics were worth $214,000 as of its most recent […] - 2025-06-02 04:34:51

Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Tidal Investments LLC

Tidal Investments LLC decreased its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 3.6% during the 4th quarter, Holdings Channel.com reports. The fund owned 9,965 shares of the biopharmaceutical company’s stock after selling 371 shares during the period. Tidal Investments LLC’s holdings in Cytokinetics were worth $469,000 at the end of the […] - 2025-05-30 05:12:51

Cytokinetics (NASDAQ:CYTK) Reaches New 52-Week Low on Analyst Downgrade

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) hit a new 52-week low during trading on Wednesday after Barclays lowered their price target on the stock from $55.00 to $53.00. Barclays currently has an overweight rating on the stock. Cytokinetics traded as low as $32.30 and last traded at $33.41, with a volume of 854150 shares […] - 2025-05-09 02:40:52

Envestnet Asset Management Inc. Reduces Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)

Envestnet Asset Management Inc. trimmed its stake in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 20.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,455 shares of the biopharmaceutical company’s stock after selling 6,612 shares during the quarter. Envestnet […] - 2025-05-01 04:36:51

Guggenheim Capital LLC Sells 4,898 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Guggenheim Capital LLC decreased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 12.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 35,988 shares of the biopharmaceutical company’s stock after selling 4,898 shares during the period. Guggenheim Capital LLC’s holdings in Cytokinetics were worth $1,693,000 as of its most recent […] - 2025-04-21 05:18:53

Bank of America Has Lowered Expectations for Cytokinetics (NASDAQ:CYTK) Stock Price

Cytokinetics (NASDAQ:CYTK – Get Free Report) had its price objective reduced by Bank of America from $62.00 to $54.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Bank of America‘s price target indicates a potential upside of 37.93% from the stock’s […] - 2025-04-17 04:48:49

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives $82.00 Average Target Price from Analysts

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) have earned an average rating of “Moderate Buy” from the eighteen analysts that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, fifteen have issued a buy recommendation and one has assigned a strong buy recommendation to the […] - 2025-04-15 02:46:42

California Public Employees Retirement System Sells 48,263 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

California Public Employees Retirement System trimmed its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 26.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 135,473 shares of the biopharmaceutical company’s stock after selling 48,263 shares during the period. California Public Employees Retirement […] - 2025-04-08 05:51:09

Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $17,743.50 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) Director Robert Arthur Harrington sold 450 shares of the company’s stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $39.43, for a total value of $17,743.50. Following the transaction, the director now directly owns 14,658 shares of the […] - 2025-04-08 05:14:51

Franklin Resources Inc. Has $25.68 Million Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)

Franklin Resources Inc. boosted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.7% in the fourth quarter, HoldingsChannel reports. The firm owned 545,813 shares of the biopharmaceutical company’s stock after purchasing an additional 9,366 shares during the quarter. Franklin Resources Inc.’s holdings in Cytokinetics were worth $25,675,000 as of its most […] - 2025-04-07 06:11:06

Prudential Financial Inc. Cuts Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)

Prudential Financial Inc. lowered its stake in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 16.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 25,336 shares of the biopharmaceutical company’s stock after selling 5,157 shares during the quarter. Prudential Financial Inc.’s holdings in Cytokinetics were worth $1,192,000 […] - 2025-04-07 04:41:04

Sei Investments Co. Sells 1,472 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Sei Investments Co. decreased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.6% during the fourth quarter, HoldingsChannel reports. The firm owned 89,560 shares of the biopharmaceutical company’s stock after selling 1,472 shares during the period. Sei Investments Co.’s holdings in Cytokinetics were worth $4,213,000 as of its most recent SEC […] - 2025-04-03 05:26:48

Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,915,821 shares of the biopharmaceutical company’s stock after purchasing an additional 154,216 shares during the […] - 2025-04-01 07:16:45

Analyzing Cytokinetics (NASDAQ:CYTK) and Portage Biotech (NASDAQ:PRTG)

Portage Biotech (NASDAQ:PRTG – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends. Volatility and Risk Portage Biotech has a beta of […] - 2025-04-01 02:57:32

Cytokinetics (NASDAQ:CYTK) and GT Biopharma (NASDAQ:GTBP) Head-To-Head Analysis

GT Biopharma (NASDAQ:GTBP – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership. Volatility and Risk GT Biopharma has a beta of […] - 2025-03-28 03:34:46

Natixis Advisors LLC Sells 3,936 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Natixis Advisors LLC lowered its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 10.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,659 shares of the biopharmaceutical company’s stock after selling 3,936 shares during the period. Natixis Advisors LLC’s holdings […] - 2025-03-25 06:30:51

Brokerages Set Cytokinetics, Incorporated (NASDAQ:CYTK) Price Target at $82.00

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eighteen research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, fifteen have issued a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-03-21 03:34:50

Back to Listing

Disclaimer